Human medicines European public assessment report (EPAR): Carmustine medac (previously Carmustine Obvius), carmustine, Date of authorisation: 18/07/2018, Revision: 10, Status: Authorised
We are more than pleased to inform you that EFIM Exchange programme is open for 2024 applications.
Each society may send one application per country. The top 10 applicants will be selected by the EFIM Executive Committee to be supported with 1000 EUR bursary given by EFIM and FDIME.
The rest of the applicants are more than welcome to participate in the Exchange programme with the support of the national society.
Deadline to submit the applications is 31 January 2024.
PDCO work plan 2024
ICH Q5A(R2) Guideline on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin - Step 5
ICH Q2(R2) Validation of analytical procedures - Scientific guideline
Committee for Orphan Medicinal Products (COMP): 3-5 October 2023, European Medicines Agency, Amsterdam, the Netherlands, 3 October 2023
List of medicines currently in PRIME scheme
Recommendations on eligibility to PRIME scheme adopted at the CHMP meeting of 11-14 December 2023
Development and manufacture of human medicinal products specifically designed for phage therapy - Scientific guideline
Human medicines European public assessment report (EPAR): Dimethyl fumarate Teva, dimethyl fumarate, Date of authorisation: 12/12/2022, Date of refusal: 12/12/2023, Status: Withdrawn